var data={"title":"Phenylephrine (systemic): Pediatric drug information \t","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Phenylephrine (systemic): Pediatric drug information \t</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390315?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=phenylephrine-systemic-drug-information\" class=\"drug drug_general\">see &quot;Phenylephrine (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=phenylephrine-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Phenylephrine (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504748\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician (injection): </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Physicians should completely familiarize themselves with the complete contents of this monograph before prescribing phenylephrine injection.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504766\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Little Colds Decongestant [OTC];</li>\n      <li>Medi-Phenyl [OTC] [DSC];</li>\n      <li>Nasal Decongestant PE Max St [OTC];</li>\n      <li>Nasal Decongestant [OTC];</li>\n      <li>Non-Pseudo Sinus Decongestant [OTC];</li>\n      <li>Sudafed PE Childrens [OTC];</li>\n      <li>Sudafed PE Congestion [OTC];</li>\n      <li>Sudafed PE Maximum Strength [OTC] [DSC];</li>\n      <li>Sudogest PE [OTC];</li>\n      <li>Vazculep</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10514172\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenergic Agonist Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Alpha-Adrenergic Agonist</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Sympathomimetic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12808756\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hypotension, low cardiac output:</b> Continuous IV infusion: Usual initial range: 0.1 to 0.5 mcg/kg/minute; titrate to desired response (Wessel, 2001); in cases of shock or intraoperative hypotension, doses up to 2 mcg/kg/minute have been reported (Kliegman, 2011; Shaddy, 1989) and for management of infundibular spasm (Tet Spell), even higher doses up to 5 mcg/kg/minute may be required (AAP, 1998; Shaddy, 1989)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10514284\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=phenylephrine-systemic-drug-information\" class=\"drug drug_general\">see &quot;Phenylephrine (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Pediatric: <b>Note:</b> Dosing presented in both mg (oral) and mcg (parenteral); use caution when ordering and dispensing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nasal congestion:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 5 years: 2.5 mg every 4 hours; maximum daily dose: 15 mg in 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to 11 years: 5 mg every 4 hours; maximum daily dose: 30 mg in 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: 10 mg every 4 hours; maximum daily dose: 60 mg in 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypotension, low cardiac output:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, SubQ: 100 mcg/kg/dose every 1 to 2 hours as needed; maximum dose: 5000 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV bolus: 5 to 20 mcg/kg/dose every 10 to 15 minutes as needed (AAP, 1998; Shaddy, 1989); initial dose should not exceed 500 mcg; maximum dose: 1000 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous  IV infusion: Usual initial dose: 0.1 to 0.5  mcg/kg/minute; titrate to desired response (Di Gennaro, 2010; Stewart, 2002; Wessel, 2001); in cases of shock or intraoperative hypotension, doses up to 2 mcg/kg/minute have been reported (Di Gennaro, 2010; Kliegman, 2011; Shaddy, 1989; Stewart, 2002) and for management of infundibular spasm (Tet Spell), even higher doses up to 5 mcg/kg/minute may be required (AAP, 1998; Shaddy, 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypotension during spinal anesthesia:</b> IM, SubQ: Infants, Children, and Adolescents: 44 to 88 mcg/kg/dose; maximum dose: 500 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypotension/shock:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV bolus: 100 to 500 mcg/dose every 10 to 15 minutes as needed (initial dose should not exceed 500 mcg)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV infusion: 100 to 180 mcg/minute, <b>or alternatively</b>, 0.5 mcg/kg/minute; titrate to desired response. Dosing ranges between 0.4 to 9.1 mcg/kg/minute have been reported (Gregory, 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nasal congestion:</b> Oral: OTC labeling: 10 mg every 4 hours as needed for &le;7 days; maximum total dose: 60 mg in 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Paroxysmal supraventricular tachycardia: Note: Not recommended for routine use in treatment of supraventricular tachycardias:</b> IV: 250 to 500 mcg over 20 to 30 seconds</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505013\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Little Colds Decongestant: 2.5 mg/mL (30 mL) [alcohol free, dye free, saccharin free; contains sodium benzoate; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (1 mL, 5 mL [DSC], 10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vazculep: 10 mg/mL (1 mL, 5 mL, 10 mL) [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/250 mL in Dextrose 5% (250 mL); 100 mg /250 mL in NaCl 0.9% (250 mL); 20 mg/250 mL in Dextrose 5% (250 mL); 20 mg/250 mL in NaCl 0.9% (250 mL); 25 mg/250 mL in NaCl 0.9% (250 mL); 40 mg/250 mL in NaCl 0.9% (250 mL); 40 mg/500 mL in NaCl 0.9% (500 mL); 50 mg/250 mL in NaCl 0.9% (250 mL); 50 mg/500 mL in Dextrose 5% (500 mL); 80 mg/250 mL in NaCl 0.9% (250 mL); 80 mg/500 mL in NaCl 0.9% (500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sudafed PE Childrens: 2.5 mg/5 mL (118 mL) [alcohol free, sugar free; contains edetate disodium, fd&amp;c red #40, sodium benzoate; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.4 mg/10 mL in NaCl 0.9% (10 mL); 0.5 mg/5 mL in NaCl 0.9% (5 mL); 0.8 mg/10 mL in NaCl 0.9% (10 mL); 1 mg/10 mL (10 mL); 1 mg/10 mL in NaCl 0.9% (10 mL); 100 mcg/10 mL in NaCl 0.9% (10 mL); 20 mg/50 mL in NaCl 0.9% (50 mL); 200 mcg/5 mL in NaCl 0.9% (5 mL); 5 mg/50 mL in NaCl 0.9% (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Medi-Phenyl: 5 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nasal Decongestant: 10 mg [contains fd&amp;c blue #2 (indigotine), fd&amp;c red #40, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nasal Decongestant PE Max St: 10 mg [pseudoephedrine free; contains fd&amp;c red #40 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Non-Pseudo Sinus Decongestant: 10 mg [contains fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sudafed PE Congestion: 10 mg [contains fd&amp;c red #40 aluminum lake, fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sudafed PE Maximum Strength: 10 mg [DSC] [contains fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sudogest PE: 10 mg [contains fd&amp;c red #40]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504775\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10514390\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: OTC products: Administer without regard to food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV bolus: Dilute and administer dose over 20 to 30 seconds (Klaus, 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: After further dilution in an appropriate fluid, administer via an infusion pump; central line administration is preferred; administration into an umbilical arterial catheter is <b>not</b> recommended. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>not</b> flush the line); remove needle/cannula; elevate extremity. Initiate phentolamine (or alternative antidote). (See Management of Drug Extravasations for more details.) Apply dry warm compresses (Hurs, 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14473054\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 20 <b>mcg</b>/mL, 40 <b>mcg</b>/mL, or 60 <b>mcg</b>/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504865\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution for injection: Store vials at controlled room temperature of 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Protect from light. Do not use solution if brown or contains a precipitate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV infusion: Concentrations of 0.1 and 0.2 mg/mL in NS are stable for at least 14 days at room temperature of 25&deg;C (77&deg;F) (Gupta 2004). Dilution of 2.5 mg/mL in NS retained potency for at least 24 hours at 22&deg;C (Weber 1970). Vazculep: Do not hold diluted solutions for longer than 4 hours at room temperature or 24 hours refrigerated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Stability in syringes: Concentration of 0.1 mg/mL in NS (polypropylene syringes) is stable for at least 30 days at -20&deg;C (-4&deg;F), 3&deg;C to 5&deg;C (37&deg;F to 41&deg;F), or 23&deg;C to 25&deg;C (73.4&deg;F to 77&deg;F) (Kiser 2007). Vazculep: Do not hold diluted solutions for longer than 4 hours at room temperature or 24 hours refrigerated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Store at controlled room temperature of 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10514175\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Treatment of hypotension and vascular failure in shock; supraventricular tachycardia; as a vasoconstrictor in regional analgesia (All indications: FDA approved adults); treatment of hypotension during spinal anesthesia (FDA approved in pediatric patients [age not specified] and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Temporary relief of nasal congestion due to the common cold, hay fever, or other upper respiratory allergies (OTC products: FDA approved in ages &ge;4 years and adults; consult specific product formulation for appropriate age group </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504764\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Sudafed PE may be confused with Sudafed</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vazculep may be confused with Bloxiverz (neostigmine) due to similar packaging</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504822\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Injection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Cardiac arrhythmia (rare), exacerbation of angina, hypertension, hypertensive crisis, ischemia, localized blanching, low cardiac output, peripheral vasoconstriction (severe), reflex bradycardia, visceral vasoconstriction (severe), worsening of heart failure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Anxiety, dizziness, excitability, headache, insomnia, nervousness, paresthesia, precordial pain (or discomfort), restlessness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Pallor, piloerection, pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Metabolic acidosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Epigastric pain, gastric irritation, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Decreased renal blood flow, decreased urine output</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction (including skin rash, urticaria, leukopenia, agranulocytosis, thrombocytopenia)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Neck pain, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Dyspnea, respiratory distress</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oral:</b> Central nervous system: Anxiety, dizziness, excitability, headache, insomnia, nervousness, restlessness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504781\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to phenylephrine or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Severe hypertension; ventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vazculep: There are no contraindications listed in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling (Oral): When used for self-medication: Use with or within 14 days of MAO inhibitor therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504782\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Intravenous use of phenylephrine may cause severe bradycardia (likely baroreflex mediated) and reduced cardiac output due to an increase in cardiac afterload especially in patients with preexisting cardiac dysfunction (Goertz 1993; Yamazaki 1982). May also precipitate angina in patients with severe coronary artery disease and increase pulmonary arterial pressure. Use with caution in patients with preexisting bradycardia, partial heart block, myocardial disease, or severe coronary artery disease. Avoid or use with extreme caution in patients with heart failure or cardiogenic shock; increased systemic vascular resistance may significantly reduce cardiac output. Avoid use in patients with hypertension (contraindicated in severe hypertension); monitor blood pressure closely and adjust infusion rate. May also cause excessive peripheral and visceral vasoconstriction and ischemia to vital organs, particularly in patients with extensive peripheral vascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: IV administration: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acidosis: Acidosis may reduce the efficacy of phenylephrine; correct acidosis prior to or during use of phenylephrine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autonomic dysfunction: Patients with autonomic dysfunction (eg, spinal cord injury) may exhibit an exaggerated increase in blood pressure response to phenylephrine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Monoamine oxidase inhibitors (MAO-I): Use with extreme caution in patients taking MAO inhibitors; hypertension may result from concurrent use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral: When used for self-medication (OTC), use with caution in patients with asthma, bowel obstruction/narrowing, hyperthyroidism, diabetes mellitus, cardiovascular disease, ischemic heart disease, hypertension, increased intraocular pressure, prostatic hyperplasia or in the elderly. Notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever. Discontinue and contact health care provider if nervousness, dizziness, or sleeplessness occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfites: Some products contain sulfites which may cause allergic reactions in susceptible individuals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: When used intravenously in patients who are hypotensive, assure adequate circulatory volume to minimize need for vasoconstrictors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: <b> [US Boxed Warning]: Intravenous preparations should be administered by adequately trained individuals familiar with its use.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26055751\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Safety and efficacy for the use of cough and cold products in pediatric patients &lt;4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in this age group. Serious adverse effects including death have been reported. Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. The FDA notes that there are no approved OTC uses for these products in pediatric patients &lt;2 years of age. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient (AAP 2012; FDA 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299870\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504824\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16040&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: May increase the serum concentration of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroprocaine: May enhance the hypertensive effect of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: May diminish the therapeutic effect of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.<b> Exceptions: </b>Ergoloid Mesylates; Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Phenylephrine (Systemic) may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details.<b> Exceptions: </b>Linezolid; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: May increase the serum concentration of Phenylephrine (Systemic). Management: Monitor patients closely for increased side effects of phenylephrine if propacetamol is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the vasopressor effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504777\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504778\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Phenylephrine crosses the placenta at term. Maternal use of phenylephrine during the first trimester of pregnancy is not strongly associated with an increased risk of fetal malformations; maternal dose and duration of therapy were not reported in available publications. Phenylephrine is available over-the-counter (OTC) for the symptomatic relief of nasal congestion. Decongestants are not the preferred agents for the treatment of rhinitis during pregnancy. Oral phenylephrine should be avoided during the first trimester of pregnancy; short-term use (&lt;3 days) of intranasal phenylephrine may be beneficial to some patients although its safety during pregnancy has not been studied. Phenylephrine injection is used at delivery for the prevention and/or treatment of maternal hypotension associated with spinal anesthesia in women undergoing cesarean section. Phenylephrine may be associated with a more favorable fetal acid base status than ephedrine; however, overall fetal outcomes appear to be similar. Nausea or vomiting may be less with phenylephrine than ephedrine but is also dependent upon blood pressure control. Phenylephrine may be preferred in the absence of maternal bradycardia. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10514391\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate, blood pressure, central venous pressure, arterial blood gases (hypotension/shock treatment)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504869\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Potent, direct-acting alpha-adrenergic agonist with virtually no beta-adrenergic activity; produces systemic arterial vasoconstriction. Such increases in systemic vascular resistance result in dose dependent increases in systolic and diastolic blood pressure and reductions in heart rate and cardiac output especially in patients with heart failure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504889\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Blood pressure increase/vasoconstriction: IM, SubQ: 10 to 15 minutes; IV: Immediate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nasal decongestant: Oral: 15 to 30 minutes (Kollar 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Blood pressure increase/vasoconstriction: IM: 1 to 2 hours; IV: ~15 to 20 minutes; SubQ: 50 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nasal decongestant: Oral: &le;4 hours (Kollar 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Erratic and incomplete (Kanfer 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Initial: 26 to 61 L; V<sub>dss</sub>: 184 to 543 L (mean: 340 L) (Hengstmann 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via oxidative deamination (Oral: 24%; IV: 50%); Undergoes sulfation (Oral [mostly within gut wall]: 46%; IV: 8%) and some glucuronidation; forms inactive metabolites (Kanfer 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: &le;38% (Hengstmann 1982; Kanfer 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Alpha phase: ~5 minutes; Terminal phase: 2 to 3 hours (Hengstmann 1982; Kanfer 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Oral: 0.75 to 2 hours (Kanfer 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (mostly as inactive metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322400\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Little Colds Decongestant Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg/mL (30 mL): $3.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Phenylephrine HCl-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20MG/250ML 5% (250 mL): $23.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50MG/500ML 5% (500 mL): $48.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Phenylephrine HCl-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10MG/250ML 0.9% (250 mL): $16.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20MG/250ML 0.9% (250 mL): $23.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25MG/250ML 0.9% (250 mL): $28.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/500 mL 0.9% (500 mL): $41.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40MG/250ML 0.9% (250 mL): $37.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50MG/250ML 0.9% (250 mL): $44.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/500 mL 0.9% (500 mL): $69.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80MG/250ML 0.9% (250 mL): $69.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100MG/250ML 0.9% (250 mL): $82.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sudafed PE Childrens Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg/5 mL (118 mL): $5.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vazculep Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (1 mL): $5.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Phenylephrine HCl-NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4MG/10ML 0.9% (10 mL): $5.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5MG/5ML 0.9% (5 mL): $5.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.8MG/10ML 0.9% (10 mL): $5.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1MG/10ML 0.9% (10 mL): $5.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100MCG/10ML 0.9% (10 mL): $6.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200MCG/5ML 0.9% (5 mL): $4.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Phenylephrine HCl-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1MG/10ML 0.9% (10 mL): $5.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/50 mL 0.9% (50 mL): $14.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/50 mL 0.9% (50 mL): $24.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sudafed PE Congestion Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (18): $6.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sudogest PE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (18): $3.79</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961999\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>AK-Dilate (PE);</li>\n      <li>Albalon Relief (AU, NZ);</li>\n      <li>Davinefrina (PT);</li>\n      <li>Denason (BR);</li>\n      <li>Drosyn (IN);</li>\n      <li>Efrin-10 (IL);</li>\n      <li>Ethifrin (PK);</li>\n      <li>Fadalefrina (AR, UY);</li>\n      <li>Fenilefrina (BR);</li>\n      <li>Fenylefrinhydroklorid (NO);</li>\n      <li>Humex Nosni (CZ);</li>\n      <li>Humoxal (FR);</li>\n      <li>Irifrin (RU);</li>\n      <li>Isonefrine (PK);</li>\n      <li>Isopto Frin (AU, EC);</li>\n      <li>Metaoxedrin (DK, NO);</li>\n      <li>Midfrin (KR);</li>\n      <li>Midriafen (CO);</li>\n      <li>Minims Phenylephrine HCL 10% (ZA);</li>\n      <li>Minims Phenylephrine Hydrochloride (GB, IE);</li>\n      <li>Mydfrin (AE, BG, BH, CN, CY, EG, HK, IQ, IR, JO, KW, LB, LY, MY, OM, PH, PY, QA, SA, SG, SY, UY, YE);</li>\n      <li>Nasalate Nose Cream (AU);</li>\n      <li>Nasenspray (CH);</li>\n      <li>Nefrisol (LK);</li>\n      <li>Neo-Sinefrina (PT);</li>\n      <li>Neo-Synephrine (IT);</li>\n      <li>Neo-Synephrine Ophthalmic (BE, DE, PH);</li>\n      <li>Neosinicin (TW);</li>\n      <li>Neosynephrin-POS (CZ, DE);</li>\n      <li>Neosynephrine Faure 10% (FR);</li>\n      <li>Oftan-Metaoksedrin (FI);</li>\n      <li>OQ-Dilat (CO);</li>\n      <li>Prefrin (AE, AR, AU, BH, CY, EC, EG, IL, IQ, IR, JO, KW, LB, LY, NZ, OM, QA, SA, SY, YE, ZA);</li>\n      <li>Qura Nasal (AR);</li>\n      <li>Visadron (AT, BE, DE, NL, PT);</li>\n      <li>We Li Ang (CL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). Five things physicians and patients should question. April 4, 2012. Available at http://www.choosingwisely.org/choosing-wisely-five-things-physicians-and-patients-should-question-press-release-april-4-2012/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. <i>Crit Care Med</i>. 2009;37(2):666-688.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-pediatric-drug-information/abstract-text/19325359/pubmed\" target=\"_blank\" id=\"19325359\">19325359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.  <a>http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Children's Sudafed PE nasal decongestant (phenylephrine systemic) [prescribing information]. McNeil PPC.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Committee on Drugs, 1996 to 1997, Liaison Representatives, and AAP Section Liaisons. Drugs for pediatric emergencies. <i>Pediatrics</i>. 1998;101(1):E13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-pediatric-drug-information/abstract-text/9734990/pubmed\" target=\"_blank\" id=\"9734990\">9734990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Di Gennaro JL, Mack CD, Malakouti A, Zimmerman JJ, Armstead W, Vavilala MS. Use and effect of vasopressors after pediatric traumatic brain injury. <i>Dev Neurosci</i>. 2010;32(5-6):420-430.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-pediatric-drug-information/abstract-text/21124016/pubmed\" target=\"_blank\" id=\"21124016\">21124016</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration (FDA). OTC cough and cold products: not for infants and children under 2 years of age. January 17, 2008. Available at <a href=\"http://www.fda.gov/forconsumers/consumerupdates/ucm048682.htm\" target=\"_blank\">http://www.fda.gov/forconsumers/consumerupdates/ucm048682.htm</a>. Last accessed January 29, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gregory JS, Bonfiglio MF, Dasta JF, Reilley TE, Townsend MC, Flancbaum L. Experience with phenylephrine as a component of the pharmacologic support of septic shock. <i>Crit Care Med</i>. 1991;19(11):1395-1400.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-pediatric-drug-information/abstract-text/1935160/pubmed\" target=\"_blank\" id=\"1935160\">1935160</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hengstmann JH, Goronzy J. Pharmacokinetics of 3H-phenylephrine in man. <i>Eur J Clin Pharmacol</i>. 1982;21(4):335-341.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-pediatric-drug-information/abstract-text/7056280/pubmed\" target=\"_blank\" id=\"7056280\">7056280</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-pediatric-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kanfer I, Dowse R, Vuma V. Pharmacokinetics of oral decongestants. <i>Pharmacotherapy</i>. 1993;13(6 Pt 2):116-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-pediatric-drug-information/abstract-text/7507589/pubmed\" target=\"_blank\" id=\"7507589\">7507589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kiser TH, Oldland AR, Fish DN. Stability of phenylephrine hydrochloride injection in polypropylene syringes. <i>Am J Health-Syst Pharm</i>. 2007;64(10):1092-1095.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-pediatric-drug-information/abstract-text/17494910/pubmed\" target=\"_blank\" id=\"17494910\">17494910</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. <i>J Pharm Technol</i>. 1989;5(3):101-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-pediatric-drug-information/abstract-text/10318297 /pubmed\" target=\"_blank\" id=\"10318297 \">10318297 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier;2011.  </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kollar C, Schneider H, Waksman J, Krusinska E. Meta-analysis of the efficacy of a single dose of phenylephrine 10 mg compared with placebo in adults with acute nasal congestion due to the common cold. <i>Clin Ther</i>. 2007;29(6):1057-1070.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-pediatric-drug-information/abstract-text/17692721/pubmed\" target=\"_blank\" id=\"17692721\">17692721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-pediatric-drug-information/abstract-text/25147175 /pubmed\" target=\"_blank\" id=\"25147175 \">25147175 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phenylephrine hydrochloride injection [prescribing information]. Shirley, NY: American regent, Inc; November 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phenylephrine hydrochloride [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; December 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS. Standardizing I.V. infusion concentrations: national survey results. <i>Am J Health Syst Pharm</i>. 2011;68(22):2176-2182.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-pediatric-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shaddy RE, Viney J, Judd VE, McGough EC. Continuous intravenous phenylephrine infusion for treatment of hypoxemic spells in tetralogy of Fallot. <i>J Pediatr</i>. 1989;114(3):468-470.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-pediatric-drug-information/abstract-text/2921691/pubmed\" target=\"_blank\" id=\"2921691\">2921691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinclair-Pingel J, Grisso AG, Hargrove FR Wright L. Implementation of standardized concentrations for continuous infusions using a computerized provider Oder Entry System. <i>Hosp Pharm</i>. 2006;41(11):1102-1106. Erratum in: <i>Hosp Pharm</i>. 2007;42:84-85. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stewart JM, Munoz J, Weldon A. Clinical and physiological effects of an acute alpha-1 adrenergic agonist and a beta-1 adrenergic antagonist in chronic orthostatic intolerance. <i>Circulation</i>. 2002;106(23):2946-2954.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-pediatric-drug-information/abstract-text/12460877/pubmed\" target=\"_blank\" id=\"12460877\">12460877</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wessel DL. Managing low cardiac output syndrome after congenital heart surgery. <i>Crit Care Med</i>. 2001;29(10 Suppl):S220-S230.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phenylephrine-systemic-pediatric-drug-information/abstract-text/11593065/pubmed\" target=\"_blank\" id=\"11593065\">11593065</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16040 Version 138.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F9504748\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9504766\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10514172\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12808756\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10514284\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9505013\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F9504775\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10514390\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14473054\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F9504865\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10514175\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9504764\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9504822\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9504781\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9504782\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26055751\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299870\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9504824\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9504777\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9504778\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10514391\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9504869\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F9504889\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322400\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961999\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16040|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=phenylephrine-systemic-drug-information\" class=\"drug drug_general\">Phenylephrine (systemic): Drug information</a></li><li><a href=\"topic.htm?path=phenylephrine-systemic-patient-drug-information\" class=\"drug drug_patient\">Phenylephrine (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}